Holmusk Announces Closing Of $21.5 Million Series A Funding Round

Holmusk, a leading data science and health technology company, announced a $21.5 million funding round. The round was led by Optum Ventures (OV) and Health Catalyst Capital (HCC) and included existing investors Heritas Capital and other individuals. The new funding round allows Holmusk to expand its US operations in New York City, and enables investment in its proprietary technology to harness and analyze real-world data to accelerate drug development and data-driven medicine.

Holmusk's real-world evidence (RWE) platform for behavioral health and chronic diseases seeks to expand data-driven, evidence-based care for people managing behavioral . . .